Dr Sam Williams
Sam has 18 years' experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and Chief Executive. From 2002 to 2007 he worked at Lehman Brothers where he was ranked the number one European biotechnology equity analyst by Institutional Investor magazine three years in a row, before becoming Industry Group Leader for Pharmaceuticals and Chemicals. Sam left Lehman Brothers in 2007 to establish Modern Biosciences (MBS), an IP Group Plc portfolio company focused on the development of novel treatments for chronic, inflammatory diseases. MBS’ lead drug for rheumatoid arthritis is currently in Phase 1 studies and is the subject of a £176m Option and Licensing deal with Janssen Biotech Inc. (J&J), signed in November 2014. As well as being CEO of MBS, Sam oversees IP Group's portfolio of biotechnology investments. He is a board member of the UK BioIndustry Association (BIA) and a non-executive director of C4X Discovery Holdings Plc. Sam has a PhD from Cambridge University and an MA in Pure and Applied Biology from Oxford University.